Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
issued a Complete Response Letter regarding Merck ’s Supplemental New
Drug Applications for JANUVIA®(sitagliptin), JANUMET®
(sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin
and metformin HCl extended-release).Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
More News: Food and Drug Administration (FDA) | Fortamet | Janumet | Januvia | Merck | Metformin | New Drug Applications | Pharmaceuticals | Study